Search

Your search keyword '"Cabeza AI"' showing total 2 results
Start Over Author "Cabeza AI" Journal european journal of clinical investigation
2 results on '"Cabeza AI"'

1. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study.

Author

López-Gálvez R, Rivera-Caravaca JM, Anguita Sánchez M, Sanmartín Fernández M, Rafols C, Pérez-Cabeza AI, Barón Esquivias G, Lekuona Goya I, Vázquez Rodríguez JM, Cosín Sales J, Arribas Ynsaurriaga F, Barrios V, Freixa-Pamias R, and Marín F

Subjects
Aged, Aged, 80 and over, Anticoagulants, Factor Xa Inhibitors therapeutic use, Female, Humans, Male, Middle Aged, Registries, Rivaroxaban therapeutic use, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Renal Insufficiency chemically induced, Stroke
Abstract

Background: In atrial fibrillation (AF) patients on vitamin K antagonists, a progressive deterioration of renal function is common but there is limited evidence with long-term use of rivaroxaban. Herein, we investigated the change in renal function in AF patients after 2 years of rivaroxaban treatment., Methods: The EMIR registry is an observational and multicentre study including AF patients treated with rivaroxaban for at least 6 months prior to inclusion. Changes in analytical parameters were recorded during 2 years of follow-up. Renal function was estimated using the Cockroft-Gault equation., Results: 1433 patients (638, 44.5% women, mean age of 74.2 ± 9.7 years) were included. Creatinine clearance (CrCl) was available at baseline and at 2 years in 1085 patients. At inclusion, 33.2% of patients had impaired renal function (CrCl <60 ml/min). At 2 years, we were not able to find changes in the proportion of patients with impaired renal function, which increased to 34.6% (p = 0.290). However, the baseline mean CrCl was 76.0 ± 30.5 ml/min and slightly improved at 2 years (77.0 ± 31.8 ml/min; p = 0.014). Overall, the proportion of patients with CrCl <60 ml/min at baseline that had CrCl ≥60 ml/min at 2 years was significantly higher compared to that of patients with CrCl ≥60 ml/min at baseline and CrCl <60 ml/min after (22.2% vs. 13.1%; p < 0.001) CONCLUSIONS: In AF patients on long-term rivaroxaban therapy, a decrease in renal function was not observed. We even observed a slight improvement in the patients with renal impairment. These results reinforce the idea that rivaroxaban may be a safe option even in patients with renal impairment., (© 2022 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

2. Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP-AF Long-term General Registry.

Author

Pérez Cabeza AI, Rivera-Caravaca JM, Roldán-Rabadán I, García Seara J, Bertomeu-Gonzalez V, Leal M, García-Fernandez A, Tercedor Sanchez L, Ayarra M, Ciudad M, Castaño S, Maestre A, Anguita M, Garcia Bolao I, and Marín F

Subjects
Administration, Oral, Aged, Aged, 80 and over, Atrial Fibrillation complications, Cohort Studies, Female, Humans, Male, Prospective Studies, Registries, Spain, Thromboembolism etiology, Time Factors, Treatment Outcome, Fibrinolytic Agents administration & dosage, Thromboembolism prevention & control
Abstract

Background: Atrial fibrillation (AF) increases the risk of thromboembolism. We investigate the efficacy and safety of oral anticoagulation (OAC) therapy and explored the number needed to treat for net effect (NNTnet) of OAC in the Spanish cohort of the EURObservational Research Programme-AF (EORP-AF) Long-term General Registry., Methods: The EORP-AF General Registry is a prospective, multicentre registry conducted in ESC countries, including consecutive AF patients. For the present analysis, we used the Spanish cohort, and the primary outcome was any thromboembolism (TE)/acute coronary syndrome (ACS)/cardiovascular death during the first year of follow-up., Results: 729 AF patients were included (57.1% male, median age 75 [IQR 67-81] years, median CHA 2 DS 2 -VASc and HAS-BLED of 3 [IQR 2-5] and 2 [IQR 1-2], respectively). 548 (75.2%) patients received OAC alone (318 [43.6%] on VKAs and 230 [31.6%] on DOACs). After 1 year, the use of OAC alone showed lower rates of any TE/ACS/cardiovascular death (3.0%/year; p < 0.001) compared to other regimens, and non-use of OAC alone (HR 4.18, 95% CI 2.12-8.27) was independently associated with any TE/ACS/cardiovascular death. Balancing the effects of treatment, the NNTnet to provide an overall benefit of OAC therapy was 24. The proportion of patients on OAC increased at 1 year (87% to 88.1%), particularly on DOACs (33.6% to 39.9%) (p = 0.015), with low discontinuation rates., Conclusions: In this contemporary cohort of AF patients, OAC therapy was associated with better clinical outcomes at 1 year and positive NNTnet. OAC use slightly increased during the follow-up, with low discontinuation rates and higher prescription of DOACs., (© 2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results